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                                       INTRODUCTION
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                   HIV infection/AIDS is a global pandemic1, with cases reported 
from virtually every country. At the end of 2007, 33.2 million individuals 
were living with HIV infection (range: 30.6–36.1 million) according to the 
Joint United Nations Programme on HIV/AIDS (UNAIDS)2. More than 95% 
of people living with HIV/AIDS reside in low and middle-income countries3 
of which 50% are female, and 2.5 million are children <15 years.
                In 2007, there were an estimated 2.5 million new cases of 
HIV infection worldwide, including 420,000 in children <15 years. In 
2007, global AIDS deaths totalled 2.1 million (including 330,000 
children <15 years). UNAIDS  estimate   that   global HIV prevalence 
has been level since 2001. HIV incidence likely peaked   in the late 
1990s at   >3 million   new infections per year.  Recent reductions in 
global HIV incidence likely reflect natural trends in the pandemic as 
well as the results of prevention programs resulting in behaviour 
change.
                Although the AIDS epidemic was first recognized in the United 
States and shortly thereafter in Western Europe, it very likely began in sub-
Saharan Africa ,  which has been particularly devastated by the epidemic. 
More than two-thirds of all people with HIV infection (about 22.5 million) 
live in that region, even though sub-Saharan Africa is home to just 10–11% 
of  the  world's  population  .Within  the  region,  southern  Africa  is  worst-
affected. In eight southern African countries, available sero prevalence  data 
indicate that >15% of the adult population aged 15–49 is HIV-infected.
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              In Asia, an estimated 4.9 million people were living with HIV at the 
end of 2007, of  which 3.6 million people are in south east Asia. In 2007 
there were 2.4 million people live with HIV/AIDS in India with an estimated 
adult HIV prevalence of 0.34%.
            The cost of combination ART has dropped in recent years as a result 
of  generic  medicines  and  differential  pricing  based  on country  need and 
ability to pay.  The cost  of diagnostic services to determine eligibility for 
treatment and to monitor treatment response has kept ART inaccessible to 
many, however. The US Department of Health and Human Services (DHHS) 
and  the  World  Health  Organization  (WHO)  recommend  initiating  ART 
therapy  based  on  consideration  of  a  patient’s  CD4  T-cell  count  when 
available. A CD4   cell count requires expensive laboratory equipment and 
trained technicians, which are absent in many areas of high HIV prevalence. 
            The cost of monitoring HIV therapy may become more prohibitive 
than the cost of the medications themselves4,5. In December 2003, the WHO 
broadened the recommendations for initiation of ART when CD4 testing is 
unavailable to include WHO stage III or IV or WHO stage II in combination 
with a TLC 1200 cells/mm3  6,7. Many studies have evaluated the use of TLC 
as  a  surrogate  marker  for  CD4+  cell  count  with  mixed  results8,9.  Some 
studies10,11,12 have found a good correlation  but  others have not. In addition 
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to low Lymphocyte count, Anaemia13,. Thrombocytopenia14,  and Body Mass 
Index (BMI)15,16 have been associated with advanced HIV infection.
            In considering the above facts ,a cross sectional study  was conducted 
in  Govt Rajaji  Hospital  using various clinical  and inexpensive laboratory 
measures  such  as  WHO  clinical  Staging  ,  Anthropometry(BMI),Total 
Lymphocyte  Count (TLC),Haemoglobin ,Platelet count,  ESR, S. Albumin 
were  done  and  compared  with  CD4  count.  It  is  analysed  that  these 
parameters can be used as a surrogate marker for CD4 count to initiate ART 
and to monitor the therapy.
                                        
                              REVIEW OF LITERATURE
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                AIDS  is  a  retroviral  disease  caused  by  the  human 
immunodeficiency virus (HIV). It is characterized by infection and depletion 
of CD4+ T lymphocytes, and by profound immune suppression leading to 
opportunistic infections, secondary neoplasm, and neurologic manifestations. 
Although AIDS was first  described in the United States,  it  has now been 
reported in virtually every country in the world. Worldwide, more than 22 
million people  have died  of  AIDS since  the  epidemic  was  recognized in 
1981; about 42 million people are living with the disease, and there are an 
estimated 5 million infections each year. Worldwide, 95% of HIV infections 
are in developing countries, with Africa alone carrying more than 50% of the 
HIV burden. Although the largest number of infections is in Africa, the most 
rapid increases in HIV infection in the past decade are in Southeast Asian 
countries, including Thailand, India, and Indonesia.
                AIDS is caused by HIV, a human retrovirus belonging to the lenti 
virus  family  (which  also  includes  feline  immunodeficiency  virus,  simian 
immunodeficiency virus,  Visna  virus of  sheep,  and the Equine infectious 
anaemia virus). Two genetically different but antigenically related forms of 
HIV, called HIV-1 and HIV-2, have been isolated from patients with AIDS. 
HIV-1 is the more common type associated with AIDS in the United States, 
Europe,  and  Central  Africa,  whereas  HIV-2  causes  a  similar  disease 
principally in West Africa. Specific tests for HIV-2 are now available, and 
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blood collected  for  transfusion  is  also  routinely  screened for  HIV-2 sero 
positivity.
                      GLOBAL PREVALENCE OF HIV
STRUCTURE AND GENOME OF HIV17
             Like most retroviruses, the HIV-1 virion is spherical and contains an 
electron-dense,  cone-shaped  core  surrounded  by  a  lipid  envelope  derived 
from the host  cell  membrane .  The virus core contains:  (1)  major  capsid 
protein p24, (2) nucleocapsid protein p7/p9, (3) two copies of genomic RNA, 
and (4) three viral enzymes (protease, reverse transcriptase, and integrase). 
p24 is the most readily detected viral antigen and is therefore the target for 
the antibodies used to diagnose HIV infection in blood screening. The viral 
core is surrounded by a matrix protein called  p17, lying beneath the virion 
envelope. 
STRUCTURE OF HIV 
               The viral envelope itself is studded by two viral glycoproteins 
(gp120 and gp41), critical for HIV infection of cells.  The HIV-1 proviral 
genome contains the  gag, pol, and  env genes, which code for various viral 
proteins. The products of the gag and pol genes are translated initially into 
large precursor proteins that must be cleaved by the viral protease to yield 
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the mature proteins. The highly effective anti-HIV-1 protease inhibitor drugs 
thus prevent  viral   assembly  by  inhibiting     the  formation of mature 
virions.  In addition to these three standard retroviral genes, HIV contains  
several other genes (given three-letter names such as  tat, rev, vif, nef, vpr, 
and  vpu)  that  regulate  the  synthesis  and  assembly  of  infectious  viral 
particles18. 
 MODES OF TRANSMISSION
Sexual Transmission
         HIV infection is predominantly a sexually transmitted disease 
(STD) worldwide the most common mode of infection, particularly in 
developing countries, is clearly heterosexual transmission.
Transmission by Blood and Blood Products
            HIV can be transmitted to individuals who receive HIV-tainted 
blood transfusions, blood products, or transplanted tissue as well as 
to IDUs who are exposed to HIV while sharing injection paraphernalia 
such as needles, syringes, the water in which drugs are mixed, or the 
cotton through which drugs are filtered.
Occupational Transmission of HIV: Health Care Workers, 
Laboratory Workers, and the Health Care Setting
                There is a small, but definite, occupational risk of HIV 
transmission to health care workers and laboratory personnel and 
potentially others who work with HIV-containing materials, particularly 
when sharp objects are used.
Maternal-Foetal/Infant Transmission
              HIV infection can be transmitted from an infected mother to 
her fetus during pregnancy, during delivery, or by breast-feeding. This 
is an extremely important form of transmission of HIV infection in 
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certain developing countries, where the proportion of infected women 
to infected men is ~1:1. 
Transmission by Other Body Fluids
                     The following fluids are considered potentially infectious: 
cerebrospinal fluid, synovial fluid, pleural fluid, peritoneal fluid, 
pericardial fluid, and amniotic fluid .
        Faeces, nasal secretions, saliva, sputum, sweat, tears, urine, 
and vomitus are not considered potentially infectious unless they are 
visibly bloody.
Life Cycle of HIV 
           The entry of HIV in to cells requires the CD4 molecule, which acts 
as a high-affinity receptor for the virus. This explains the tropism of the 
virus for CD4+ T cells and its ability to infect other CD4+ cells, 
particularly macrophages and DCs. However, binding to CD4 is not 
sufficient for                                                     infection; the HIV envelope 
gp120 must also bind to other cell surface molecules (coreceptors) to 
facilitate cell entry. Two cell surface chemokine receptors, CCR5 and 
CXCR4, serve this role19,20 .
          HIV envelope gp120 (non covalently attached to transmembrane 
gp41)  binds  initially  to  CD4  molecules  .This  binding  leads  to  a 
conformational change that exposes a new recognition site on gp120 for the 
CXCR4 (mostly on T cells) or CCR5 (mostly on macrophages) coreceptors. 
The gp41 then undergoes a conformational change that allows it to insert 
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into the target membrane, and this process facilitates fusion of the virus with 
the cell21. 
             The coreceptors are critical components of the HIV infection 
process. HIV strains could be classified according to their relative ability to 
infect  macrophages  and/or  CD4+  T  cells.  Macrophage-tropic  (R5  virus) 
strains infect  both monocytes/macrophages and freshly isolated peripheral 
blood T cells, whereas T-cell tropic (X4 virus) strains infect only activated T 
cell lines.
R5 strains use CCR5 as their coreceptor, and, because CCR5 is expressed on 
both monocytes and T cells, these cells succumb to infection by R5 strains. 
Conversely, X4 strains bind to CXCR4, which is expressed on T cell lines 
(and not on monocytes/macrophages), so that only activated T cells are 
susceptible.                                       
 LIFE CYCLE OF HIV
Interestingly, approximately 90% of HIV infections are initially transmitted 
by R5 strains. However, over the course of infection, X4 viruses gradually 
accumulate;  these  are  especially  virulent  and  are  responsible  for  T-cell 
depletion in the final rapid phase of disease progression22,23. 
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               It is thought that during the course of HIV infection, R5 strains 
evolve into X4 strains, as a result of mutations in genes that encode gp120. 
The resultant transition in the ability of the virus to bind CXCR4 but not 
CCR5 is probably important in the pathogenesis of AIDS because T tropic 
(CXCR4)viruses are capable of infecting naive T cells and even thymic T 
cell precursors and cause greater T Cell depletion and impairment.
           Once internalized, the viral genome undergoes reverse transcription, 
leading to formation of complementary DNA (cDNA). In quiescent T cells, 
HIV proviral  cDNA may remain in the cytoplasm in a linear episomal form. 
However,  in dividing T cells,  the cDNA enters the nucleus and becomes 
integrated into the host genome. After integration, the provirus may remain 
non  transcribed  for  months  or  years,  and  the  infection  becomes  latent; 
Alternatively,  proviral  DNA  may  be  transcribed  to  form  complete  viral 
particles  that  bud  from  the  cell  membrane.  Such  productive  infections, 
associated with extensive viral budding, lead to cell death.
MECHANISM  OF  CD4+  T  CELL  DYSFUNCTION  AND 
DEPLETION24,25,26
DIRECT MECHANISMS
INDIRECT MECHANISMS
1.Loss of plasma membrane integrity due to viral budding
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1. Aberrant intracellular signalling events
2.Autoimmunity
2. Accumulation of unintegrated viral DNA
3. Innocent bystander killing of viral antigen–coated cells
3.Interference with cellular RNA processing
4. Apoptosis
4. Intracellular gp120-CD4 autofusion events
5. Inhibition of lymphopoiesis
5. Syncytia formation
6. Activation-induced cell death
7.Elimination of HIV-infected cells by virus-specific immune 
responses
MAJOR ABNORMALITIES OF IMMUNE FUNCTION IN AIDS
    Lymphopenia
    Predominantly caused by selective loss of the CD4 helper T-cell subset;     
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    inversion  of CD4:CD8 ratio.
    Decreased T-Cell Function in Vivo
    Preferential loss of activated and memory T cells.
    Decreased delayed-type hypersensitivity.
    Susceptibility to opportunistic infections.
    Susceptibility to neoplasm.
    Altered T-Cell Function in Vitro
     Decreased  proliferative  response  to  mitogens,  alloantigens,  and  soluble 
antigens
    Decreased cytotoxicity.
    Decreased helper function for B-cell antibody production.
    Decreased IL-2 AND IFN- γ production.
    Altered Monocyte or Macrophage Functions
    Decreased chemotaxis and phagocytosis.
    Decreased HLA class II antigen expression.
    Diminished capacity to present antigen to T cells.
    Increased spontaneous secretion of IL-1, TNF, IL-6.
     Polyclonal B-Cell Activation
     Hypergammaglobulinemia and circulating immune complexes.
     Inability to mount de novo antibody response to a new antigen.
     Poor responses to normal signals for B-cell activation in vitro.
Diagnosis and laboratory monitoring of HIV infection
           The establishment of HIV as the causative agent of AIDS and 
related syndromes early in 1984 was followed by the rapid 
development of sensitive screening tests for HIV infection. By March 
1985, blood donors in the United States were routinely screened for 
antibodies to HIV. In June 1996, blood banks in the United States 
added  the p24 antigen capture assay to the screening process to 
help identify the rare infected individuals who were donating blood in 
the time (up to 3 months) between infection and the development of 
antibodies. 
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DIAGNOSIS OF HIV INFECTION
           The CDC has recommended that screening for HIV infection 
be performed as a matter of routine health care. The diagnosis of HIV 
infection depends upon the demonstration of antibodies to HIV and/or 
the direct detection of HIV or one of its components. As noted above, 
antibodies to HIV generally appear in the circulation 2–12 weeks 
following infection.
ANTIBODY DETECTION BY ELISA/EIA :
          This is the most widely used screening method. It has a sensitivity of 
more than 99.5 %.  Hence the false positivity is also present   with conditions 
such as influenza vaccination, hepatic disease auto antibodies. Direct solid 
phase anti globulin ELISA is the most commonly used method. 
WESTERN BLOT
          The most commonly used confirmatory test is the Western blot . This 
assay takes advantage of the fact that multiple HIV antigens of different, 
well-characterized  molecular  weights  elicit  the  production  of  specific 
antibodies. These antigens can be separated on the basis of molecular weight, 
and antibodies to each component can be detected as discrete bands on the 
Western blot. 
LABORATORY  MONITORING  OF  PATIENTS  WITH  HIV 
INFECTION27
           The epidemic of HIV infection and AIDS has provided the 
clinician with new challenges for integrating clinical and laboratory 
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data to effect optimal patient management. The close relationship 
between clinical manifestations of HIV infection and CD4+ T cell 
count has made measurement of the latter a routine part of the 
evaluation of HIV-infected individuals. Determinations of CD4+ T cell 
counts and measurements of the levels of HIV RNA in serum or 
plasma provide a powerful set of tools for determining prognosis and 
monitoring response to therapy.
CD4+ T CELL COUNTS
          The CD4+ T cell count is the laboratory test generally accepted 
as the best indicator of the immediate state of immunologic 
competence of the patient with HIV infection. This measurement, 
which can be made directly or calculated as the product of the 
percent of CD4+ T cells (determined by flow cytometry) and the total 
lymphocyte count [determined by the white blood cell count (WBC) 
and the differential percent], has been shown to correlate very well 
with the level of immunologic competence. 
            Patients with CD4+ T cell counts <200/µL are at high risk of 
disease from P. jiroveci, while patients with CD4+ T cell counts 
<50/µL are at high risk of disease from CMV, mycobacteria of the M. 
avium complex (MAC) and/or T. gondii . 
         Patients with HIV infection should have CD4+ T cell 
measurements performed at the time of diagnosis and every 3–6 
months thereafter. More frequent measurements should be made if a 
declining trend is noted. 
         According to most guidelines, a CD4 T cell count <350/µL is an 
indication for consideration of initiating ARV therapy, and a decline in 
CD4+ T cell count of >25% is an indication for considering a change 
in therapy. 
          Once the CD4+ T cell count is <200/µL, patients should be 
placed on a regimen for P.jiroveci prophylaxis, and once the count is 
<50/µL, primary prophylaxis for MAC infection is indicated. As with 
any laboratory measurement, one may wish to obtain two 
determinations prior to any significant changes in patient 
management based upon CD4+ T cell count alone.  In patients with 
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hypersplenism or who have undergone splenectomy the CD4+ T cell 
percentage may be a more reliable indication of immune function than 
the CD4+ T cell count. A CD4+ T cell percent of 15 is comparable to a 
CD4+ T cell count of 200/µL.
CD4 LEVELS IN RELATION TO SEVERITY OF IMMUNO SUPPRESSION
Not significant immunosuppression
>500 cells/µL
Mild immunosuppression
350 – 499 cells/µL
Advanced immunosuppression
200 −349 cells/µL
Severe immunosuppression
<200 cells/µL
HIV RNA DETERMINATIONS
           Facilitated by highly sensitive techniques for the precise 
quantification of small amounts of nucleic acids, the measurement of 
serum or plasma levels of HIV RNA has become an essential 
component in the monitoring of patients with HIV infection. The two 
most commonly used techniques are the RT-PCR assay and the 
bDNA assay. HIV RNA measurements are greatly influenced by the 
state of activation of the immune system and may fluctuate greatly in 
the setting of secondary infections or immunization. For these 
reasons, decisions based upon HIV RNA levels should never be 
made on a single determination. Measurements of plasma HIV RNA 
levels should be made at the time of HIV diagnosis and every 3–6 
months thereafter in the untreated patient. In general, most guidelines 
suggest that therapy be considered in patients with >100,000 copies 
of HIV RNA per milliliter.
           HIV RNA measurements are to be done frequently to monitor 
therapy, which  has  great  economic burden to  many people in 
developing countries. Hence the need other simple clinical or 
laboratory parameter to monitor therapy is essential in developing 
countries.
OTHER TESTS
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        A variety of other laboratory tests have been studied as potential 
markers of HIV disease activity. Among these are quantitative culture 
of replication-competent HIV from plasma, peripheral blood 
mononuclear cells, or resting CD4+ T cells; circulating levels of 
β2microglobulin, soluble IL-2 receptor, IgA, acid-labile endogenous 
interferon, or TNFα; and the presence or absence of activation 
markers such as CD38, HLA-DR, or PD-1 on CD8+ T cells. While 
these measurements have value as markers of disease activity and 
help to increase our understanding of the pathogenesis of HIV 
disease, they do not currently play a major role in the monitoring of 
patients with HIV infection.
             Hence in our study various clinical and inexpensive laboratory 
measures  such  as  clinical  Staging  WHO,  Anthropometry  (BMI),Total 
Lymphocyte  Count (TLC),haemoglobin ,platelet count,  ESR, S. Albumin 
were done to assess HIV disease activity and compared with CD4 count. 
Then ,it  was  analysed  that  these  parameters  may  be  used  as  a  surrogate 
marker for CD4 count to initiate ART and to monitor the therapy.
CLINICAL MANIFESTATIONS:
         The clinical consequences  of HIV encompasses a spectrum 
ranging from an acute syndrome associated with primary infection to 
a prolonged asymptomatic state to advanced disease.
THE ACUTE HIV SYNDROME:
          The acute phase represents the initial response of an 
immunocompetent adult to HIV infection. Clinically, this is typically a 
self-limited illness that develops in 50% to 70% of adults 3 to 6 weeks 
after infection; it is characterized by nonspecific symptoms including 
sore throat, myalgia, fever, rash, and sometimes aseptic meningitis.
The Asymptomatic Stage—Clinical Latency
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          Although the length of time from initial infection to the 
development of clinical disease varies greatly, the median time for 
untreated patients is approximately 10 years. HIV disease with active 
virus replication is ongoing and progressive during this asymptomatic 
period. 
The middle, chronic phase represents a stage of relative containment of the 
virus.  The  immune  system  is  largely  intact  at  this  point,  but  there  is 
continued HIV replication that may last for several years. Patients either are 
asymptomatic  or  develop persistent  lymphadenopathy,  and  many  patients 
have "minor" opportunistic infections such as  thrush (Candida)  or  herpes 
zoster. During this phase, viral replication in the lymphoid tissues continues 
unabated. The extensive viral turnover is associated with continued loss of 
CD4+ cells, but a large proportion of the CD4+ cells is replenished and the 
decline of CD4+ cells in the peripheral blood is modest.
Symptomatic Disease
           The final, crisis phase is characterized by a catastrophic breakdown of 
host defenses, a marked increase in viremia, and clinical disease. Typically, 
patients present with fever of more than 1 month's duration, fatigue, weight 
loss,  and diarrhoea;  the CD4+ cell  count  is  reduced below 500 cells/μL. 
After a variable interval,  patients develop serious opportunistic infections, 
secondary  neoplasm,  and/or  neurologic  manifestations  (so-called  AIDS-
defining conditions), and the patient is said to have full-blown AIDS.
23
           A diagnosis of AIDS is made in anyone with HIV infection and a 
CD4+ T cell count <200/µL and in anyone with HIV infection who develops 
one of the HIV-associated diseases considered to be indicative of a severe 
defect in cell-mediated immunity .
Revised  World  Health  Organization  (WHO)  Clinical  Staging  of 
HIV/AIDS For Adults and Adolescents (2005)28
Primary HIV infection
• Asymptomatic
• Acute retroviral syndrome
 Clinical stage 1
• Asymptomatic
• Persistent generalized lymphadenopathy
Clinical stage 2
• Moderate and unexplained weight loss (<10percent; of presumed or 
measured body weight)
• Recurrent  respiratory  tract  infections  (such  as  sinusitis,  bronchitis, 
otitis media, pharyngitis)
• Herpes zoster
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• Recurrent oral ulcerations
• Papular pruritic eruptions
• Angular cheilitis
• Seborrhoeic dermatitis
• Fungal finger nail infections
Clinical stage 3
Conditions where a presumptive diagnosis can be made on the 
basis of clinical signs or simple investigations
• Unexplained chronic diarrhoea for longer than one month
• Unexplained persistent fever (intermittent or constant for longer than 
one month)
• Severe  weight  loss  (>10percent;  of  presumed  or  measured  body 
weight)
• Oral candidiasis
• Oral hairy leukoplakia
• Pulmonary tuberculosis (TB) diagnosed in last two years
• Severe  presumed  bacterial  infections  (e.g.  pneumonia,  empyema, 
meningitis, bacteraemia, pyomyositis, bone or joint infection)
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• Acute necrotizing ulcerative stomatitis, gingivitis or periodontitis
Conditions where confirmatory diagnostic testing is necessary
• Unexplained anaemia (< 80 g/l), and or neutropenia (<500/µl) and or 
thrombocytopenia (<50 000/ µl) for more than one month
Clinical stage 4
Conditions where a presumptive diagnosis can be made on the 
basis of clinical signs or simple investigations
• HIV wasting syndrome
• Pneumocystis pneumonia
• Recurrent severe or radiological bacterial pneumonia
• Chronic  herpes  simplex  infection (orolabial,  genital  or  anorectal  of 
more than one month’s duration)
• Oesophageal candidiasis
• Extrapulmonary Tuberculosis
• Kaposi’s sarcoma
• Central nervous system toxoplasmosis
• HIV encephalopathy
Conditions where confirmatory diagnostic testing is necessary
• Extrapulmonary cryptococcosis including meningitis
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• Disseminated non-tuberculous mycobacteria infection
• Progressive multifocal leukoencephalopathy
• Candida of trachea, bronchi or lungs
• Cryptosporidiosis
• Isosporiasis
• Visceral herpes simplex infection
• Cytomegalovirus (CMV) infection (retinitis or of an organ other than 
liver, spleen or lymph nodes)
• Any  disseminated  mycosis  (e.g.  histoplasmosis,  coccidiomycosis, 
penicilliosis)
• Recurrent non-typhoidal salmonella septicaemia
• Lymphoma (cerebral or B cell non-Hodgkin)
• Invasive cervical carcinoma
• Visceral leishmaniasis
The aim  of  proposed revisions of WHO staging were to:
◗ facilitate  the  use  of  the  clinical  staging  system  and  HIV/AIDS  case 
definitions by non-specialist and  at the basic level and in peripheral health 
care facilities;
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◗ assist  with  clinical  decision-making,  including  decisions  on  starting, 
substituting,  switching and stopping ART,  and with routine  follow up of 
patients on treatment;
ANTHROPOMETRY
        HIV wasting, or an unintentional weight loss of more than10% of 
normal weight, is a common AIDS-defining condition29.
         HIV-associated weight loss is an independent predictor of opportunistic 
infections, hospitalisation and mortality .It was postulated that HIV wasting 
is a cachectic process in which weight loss is disproportionately loss of lean 
body mass, with relative conservation of fat. Loss of fat was deemed a poor 
marker of AIDS wasting. Proposed mechanisms for muscle wasting include 
altered cytokine   levels30    and  alterations in circulating levels of anabolic 
sex hormones.
       Anthropometry  especially  BMI   is  useful  to  asses  the  disease 
progression.
JE Forrester1, D Spiegelman, M Woods 49 conducted a study on “Weight 
and body composition in a cohort  of HIV-positive men and women”.516 
persons  were  enrolled  in  the  study.  According  to  this  study  there  was  a 
significant trend towards lower weight and BMI with lower CD4 counts.
TOTAL LYMPHOCYTE COUNT (ABSOLUTE LYMPHOCYTE COUNT)
           TLC is easily obtained from the routine complete blood count (CBC)
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with differential through multiplication of lymphocyte percentage by white 
blood cell count.
                       TLC= % of lymphocyte  x  total WBC count
         TLC has been suggested as a measure of when to initiate both HAART 
and prophylaxis against opportunistic illness in resource-limited settings.
In December 2003, the WHO issued  the recommendations for initiation of 
ART when CD4 testing is unavailable to include WHO stage III or IV or 
WHO stage II in combination with a TLC <1200 cells/mm³ 31,32,33. 
         Caroline Costello, MPH, Kenrad E. Nelson, MD43, conducted a 
study  in  thai  population  on  “Predictors  ofLowCD4Count  in  Resource-
Limited Settings”. In this study TLC<1200 cells/mm³ has good correlation 
with CD4<200 Cells/µL.A Total Lymphocyte Count (TLC) cut off at <1200 
cells/mm³  improved  the  sensitivity  above  that  of  meeting  the  WHO 
guidelines for onset of antiretroviral therapy while maintaining a specificity 
above 99%. 
S.M. Alavi , F. Ahmadi  et al conducted a study on “Correlation between 
Total  Lymphocyte  Count,  Haemoglobin,  Haematocrit  and  CD4 Count  in 
HIV/AIDS Patients”. In this study a strong correlation was observed between 
CD4 count and TLC.
ANAEMIA
       Disorders of the hematopoietic system including 
lymphadenopathy, anaemia34, leukopenia, and/or thrombocytopenia 
are common throughout the course of HIV infection and may be the 
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direct result of HIV, manifestations of secondary infections and 
neoplasm, or side effects of therapy . 
         Anaemia27 is the most common hematologic abnormality in HIV-
infected patients and in the absence of a specific treatable cause is 
independently associated with a poor prognosis. Among the specific 
reversible causes of anaemia in the setting of HIV infection are drug 
toxicity, systemic fungal and mycobacterial infections, nutritional 
deficiencies, and parvovirus B19 infections. Folate levels are usually 
normal in HIV-infected individuals; however, vitamin B12 levels may be 
depressed as a consequence of achlorhydria  or  malabsorption. 
                  True autoimmune haemolytic anaemia is rare, although 
~20% of patients with HIV infection may have a positive direct 
antiglobulin test as a consequence of polyclonal B cell activation. 
Erythropoietin levels in patients with HIV infection and anaemia are 
generally less than expected given the degree of anaemia. Treatment 
with erythropoietin at doses of 100 µg/kg three times a week may 
result in an increase in haemoglobin levels.
        During the course of  HIV infection,  neutropenia may be seen in 
approximately half of patients. In most instances it is mild; however, it can 
be severe and can put patients at  risk of spontaneous bacterial  infections. 
This is most frequently seen in patients with severely advanced HIV disease 
and in patients receiving any of a number of potentially myelosuppressive 
therapies34. 
     
        Many studies are conducted worldwide.47 Belperio PS, Rhew DC. 
Prevalence    and  outcomes  of  anaemia   in  individuals  with  human 
immunodeficiency virus. In this study it was found that anaemia was  more 
commonly associated with disease progression with progressive decrease in 
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CD4 count .  Mocroft A, Kirk O, Barton SE, et al. Conducted a study on 
“Anaemia is an independent predictive marker for clinical prognosis in HIV-
infected  patients”  from  across  Europe.  In  this  study   it  was  found  that 
anaemia was a  independent predictor of mortality in HIV infected patients48.
PLATELET COUNT
        Thrombocytopenia14 may be an early consequence of HIV infection. 
Approximately 3% of patients with untreated HIV infection and CD4+ T cell 
counts  ³400/µL have  platelet  counts  <150,000/µL.  For  untreated  patients 
with  CD4+  T  cell  counts  <400/µL,  this  incidence  increases  to  10%. 
Thrombocytopenia is rarely a serious clinical problem in patients with HIV 
infection  and  generally  responds  well  to  ARV  therapy.  Clinically,  it 
resembles  the  thrombocytopenia  seen  in  patients  with  idiopathic 
thrombocytopenic purpura.
           Immune complexes containing anti-gp120 antibodies and anti-anti-
gp120 antibodies have been noted in the circulation and on the surface of 
platelets in patients with HIV infection. Patients with HIV infection have 
also been noted to have a platelet-specific antibody directed toward a 25-kDa 
component  of  the  surface  of  the  platelet.  Other  data  suggest  that  the 
thrombocytopenia  in  patients  with  HIV infection  may  be due  to  a  direct 
effect of HIV on megakaryocytes.
          Sullivan  and  colleagues45 evaluated  the  1-year  incidence  of 
thrombocytopenia(<50,000/mm3) in a group of 30,214 HIV infected patients. 
31
The incidence of thrombocytopenia during 1 year was 8.7% in patients with 
clinical  AIDS,3.1% in patients  with immunologic AIDS(CD4 count <200 
cells/µL).Over time, development of thrombocytopenia was associated with 
clinical or immunologic AIDS, history of injection use, anaemia, lymphoma 
and African race. After controlling for multiple factors (AIDS,CD4 count, 
anaemia,  neutropenia,   ART  therapy,  prophylaxis  against  p.carnii) 
thrombocytopenia  was  significantly  associated  with  shorter  survival  (risk 
ratio,1.7:95% confidence interval = 1.6-1.8)
SERUM ALBUMIN
         S.albumin levels decreases progressively with progression of 
disease to AIDS. It correlate well with low CD4 count.  Even though 
serum albumin is not a specific marker for HIV-1 infection, it was one 
of the strongest independent predictors of mortality.
      Because HIV infection is known to be associated with systemic 
inflammation and elevations in the levels of proinflammatory 
cytokines, a strong association of albumin and mortality would be 
expected in HIV patients.
The mechanism of reduced albumin in HIV are
1.proinflammatory cytokines suppress albumin35 synthesis.
2. the HIV-1 Tat-1 protein may disrupt the barrier function of the 
endothelium, resulting in both an increase in trans capillary escape of 
albumin and the dissemination of HIV-infected cells into tissue and, 
consequently, disease progression36.
3. HIV-related anorexia may depress albumin synthesis, although 
albumin is not regarded as a sensitive marker of nutrition, especially 
in the short term37. 
4. the onset of HIV-associated nephropathy will increase renal losses 
of albumin
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  Joseph G. Feldman46, Stephen J. Gange , conducted a study on 
“Serum Albumin Is a Powerful Predictor of Survival among HIV-1–
Infected Women”. This was a multicenter prospective study of the 
natural history of HIV-1 infection in women conducted in five United 
States cities. According to this study Albumin fell 0.44 g/L/y in 1627 
women who survived and at a faster rate in 397 who died (1.54 g/L/y; 
p < .01). In a time-dependent model adjusting for disease markers, 
the relative hazard (RH) was fivefold higher in patients with serum 
albumin <35 g/L compared with patients with serum albumin >42 g/L. 
                        AIM OF THE STUDY
1.To find out the best predictor of CD4 count  in HIV infected patients, 
among  the selected clinical parameters (WHO staging, 
anthropometry) and laboratory parameters(Total Lymphocyte Count, 
Haemoglobin, platelet count, ESR, Serum Albumin).
2. To study the correlation between these parameters and CD4 count 
to suggest that these can be used as a surrogate for CD4 count to 
initiate ART in resource limited settings.
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                         MATERIALS AND METHODS
SETTING:
         About 100 documented HIV positive patients attending ART centre 
and admitted  in  various  medical  wards  in  Govt.  Rajaji   Hospital    were 
studied.
COLLABORATIVE DEPARTMENTS:
             Department of STD  , Anti Retroviral Therapy centre,
             Department of pathology and Biochemistry,
             Madurai medical college,
             Madurai.
STUDY DESIGN:
             Analytical Study
PERIOD OF STUDY:
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             June 2008- June 2009
SAMPLE SIZE:
              About 100 Patients with documented HIV+ using ELISA.
ETHICAL CLEARANCE:
Necessary ethical clearance was obtained from Ethical committee ,  GRH, 
Madurai
CONSENT: informed consent was obtained
FINANCIAL SUPPORT: NIL
CONFLICT OF INTEREST: NIL
INCLUSION CRITERIA:
          patients with documented  HIV + were included in this study.
EXCLUSION CRITERIA:
Patient on ART therapy
Patients   on Anti Tubercular Therapy (ATT)
Patients on steroid, iron  or vitamin therapy
Patient with bleeding disorder
Pregnancy 
Diabetes and other metabolic disorders
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Chronic renal failure patients
METHODS
             After obtaining the verbal consent either from the patient or the 
relatives,  all  patients  were  evaluated    by  complete  medical  history and 
standardized baseline investigations  such as blood sugar, blood urea ,serum 
creatinine and liver function tests  were done.                       
             All patients underwent through a list of questionnaire   and detailed 
clinical examination to stage (I ,II, III,IV ) according to WHO CLINICAL 
STAGING REVISED CRITERIA 200528  as per proforma. Anthropometric 
measurements such as BMI was calculated.
The following specific investigation was done in patients
                1. CD4 count
                2. Total Lymphocyte Count(TLC)
                3. Haemoglobin(HB)
                4. Platelet count(PLT)
               5. Erythrocyte Sedimentation Rate (ESR)
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               6. Serum Albumin.
CD4 COUNT:
CD4 count was done using Flow Cytometry.  Flow cytometers use lasers to 
excite fluorescent antibody probes specific for various cell surface markers, 
such as CD3, CD4, and CD8.It is calculated in cells/µL.
 AUTOMATED CELL COUNTER: 
                 Total WBC count, Differential count, Haemoglobin, Platelet count 
were obtained using   automated cell counter.
                Automated cell counters sample the blood, and quantify classify 
and describe the cell populations using both electrical and optical techniques.
               Total lymphocyte count was easily obtained from total WBC count 
and differential percentage of lymphocyte using the following formula.
                    TLC =  % of lymphocyte  x  total WBC count 
                Normal TLC   is usually > 1800 cells/mm³.
ESR:
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 ESR was obtained using westergren tube. Anticoagulated blood is placed in 
a  upright  westergren  tube  and  rate  at  which  the  RBC's  sedimented   is 
measured and reported in mm/hr  .
The   normal values  are  
MEN   <50 years   - <13 mm/hr and 
           > 50 years -  <20 mm/hr
WOMEN    < 50 years - < 20mm/hr
              >50 years- < 30 mm/hr
LIMITATIONS OF OUR STUDY:
  WHO clinical staging in our cases were done on presumed clinical basis 
and some basic laboratatory investigations,so some of the patients may be 
wrongly staged.
Statistical Tools 
The  information  collected  regarding  all  the  selected  cases  were 
recorded  in  a  Master  Chart.  Data  analysis  was  done  with  the  help  of 
computer using Epidemiological Information Package (EPI 2008).
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Using this software range, frequencies, percentages, means, standard 
deviations, chi square and   'p'  values were calculated. Kruskul Wallis chi-
square   test  was  used  to  test  the  significance  of  difference  between 
quantitative variables and Yate’s test  for qualitative variables.  A 'p'  value 
less than 0.05 is taken to denote significant relationship.
Sensitivity, specificity, accuracy, positive predictive value and 
negative predictive values were calculated using the following 
formulae
Sensitivity = True positive x 100
True positive + False negative
Specificity = True negative x 100
False positive + True negative
Accuracy = True Positive + True Negative x 100
Total cases
Positive predictive value = True positive x 100
True positive + False positive
Negative predictive value = True negative          x 
100
True negative + False negative
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                                              RESULTS
Figure 1:   AGE DISTRIBUTION       
              
TABLE 1:           AGE DISTRIBUTION
AGE GROUP( in years)
             CASES
40
No. %
13 -20 3 3
21-30 20 20
31-40 54 54
41-50 17 17
>50 6 6
                      
                     Total 100 100
Range 18-60 years
Mean 35.9  years
SD 8.5  years
          In our study about 54% of people were in age group between 31-40 
years.91%  of  patients  are  age  group  between  21-50  yrs.  so  majority  of 
patients in our study were in reproductive age group.
Figure 2: GENDER DISTRIBUTION
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TABLE 2: GENDER DISTRIBUTION
SEX CASES
No. %
Male 66 66
Female 34 34
Total 100 100
        In our study about 66% of patients were males and 34% were females.
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TABLE 3:MARITAL STATUS
MARITAL STATUS CASES CD4 COUNT
No. % mean SD
Married 66 66   265.8 212.6
Unmarried 21 21 299.4 233.7
Separated 13 13 234.8 215.3
Total 100 100 p    0.5441
  Not significant
           As shown in above table ,most of the patients about 79% were 
married of which 13% of patients were separated after marriage and living 
alone.21% of patients were unmarried. Marital status when correlated with 
CD4 count ,p value was not statistically significant.
 TABLE 4 : PREMARITAL SEX
PREMARITAL SEX CASES
No. %
Yes 42 42
No 58 58
Total     100     100
             In the above table about 58% of the patients denies history of 
premarital sex and 42% gives positive history of premarital sex.
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TABLE 5: EXTRA MARITAL PATNERS
EXTRAMARITAL
PATNERS
CASES CD4 COUNT
No. % MEAN SD
None 22 22 258.4 201.5
single 24 24 92.5 53.0
Multiple >1 54 54 603.5 327.6
Total 100 100 p value 0.0185 significant
              As shown in above table , 54% of the patients were having more 
than  one  extra  marital  patners.22%  of  the  patients  had  no  extramarital 
exposure. Extra marital sex when correlated with CD4 count, p value 0.0185 
was significant.
Figure 3 :  OCCUPATION
44
TABLE 6: EDUCATION
EDUCATION CASES CD4 COUNT
No. % MEAN SD
<10 TH Std 54 54 230.1 189.1
10-12 th Std 36 36 291.1 212.2
Higher Education 10 10 394.6 314.9
TOTAL 100 100 p value 0.0778
Not  significant
          
 As shown in above table Majority of the patients in our study i e. about 54% 
were less educated ( below tenth standard) whereas only 10% of the patients 
studied higher education. Education when correlated with CD4 count p value 
0.0778 was not significant.
TABLE 7: OCCUPATION
OCCUPATION CASES
No. %
Labourer 58 58
Drivers 11 11
House Wife 20 20
Business Men 6 6
Service Men 3 3
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Police Men 1 1
Student 1 1
          
 Most of the patients 58% in the study group were labourers as shown in 
Table-7 and Fig 3. Housewives constitutes 20% of study population. Drivers 
accounted for 11% and Business men constitutes 6%.
TABLE 8: ECONOMIC STATUS
ECONOMIC 
STATUS
CASES CD4
No. % MEAN SD
Upper 7 7 687.1 330.5
Middle 21 21 336.9 194.2
Lower 72 72 208.3 151.3
Total 100 100 p value 0.0001
significant
          In our study about 72% of the patients were in lower socio economic 
status,21% of patients belong  to middle class, only 7% of the patients were 
in upper economic status. Economic status has significant p value 0.0001 
when correlated with CD4 count.
TABLE 9: EXPOSURE TYPE
EXPOSURE CASES
No. %
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Heterosexual 94 94
Homosexual 2 2
Blood Products 4 4
Iv Drug Abuser - -
Needle Stick - -
Materno Foetal - -
          The above table shows that the heterosexual mode of transmission was 
the commonest mode of transmission, accounting for 94% of the cases. only 
2% of cases transmission was through homosexual route and 4% of cases 
showed transmission through blood products such as blood transfusion.
Figure 4 : STAGING AND CD4 COUNT
TABLE10: STAGING AND CD4 COUNT
STAGING cases CD4
No . % MEAN SD
I 17 17 571.2 228
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II 9 9 434.4 291.2
III 43 43 210.1 100.3
IV 31 31 136.4 80.7
 100 100 p value 0.0001
significant
          As shown in the above table, about 74% of the patients were  came 
under stage III & IV of WHO staging. When staging was correlated with 
CD4 count  the   p  value  was statistically significant. patients with Stage IV 
had average CD4 count of 136.4 cells/µL and Stage III had 210 cells/µL. 
whereas  stage  I  and  II  had  average  count  of  571.2  and  434.4  cells/µL 
respectively as shown in Figure 4.
TABLE 11: OTHER LABORATORY PARAMETERS
RANGE MEAN SD
CD4 cells/µL 31-1050 269 216
TLC cells/mm³ 184-3020 1316 696
TC  cells/mm³ 1840-9400 6199 1537
HB g/dl 3.2-14.4 8.41 2.68
HT cm 140-178 162 9.4
WT kg 38-70 47.9 7.2
BMI kg/m² 14.2-25.4 18.2 2.2
PLATELET 40000-420000 180910 91177
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ESR mm/hr 4-112 41.4 29.1
S.albumin g/dl 2.3-4.5 3.28 0.61
Figure 5: TOTAL   LYMPHOCYTE  COUNT AND CD4 COUNT
   
TABLE  12 : TOTAL LYMPHOCYTE COUNT AND CD4 COUNT
TLC CASES CD4
No. % MEAN SD
<1200 48 48 121.9 52.8
1200-1800 10 10 266.3 51.7
>1800 42 42 565.8 234.5
Total 100 100 p value 0.0001
Significant
            Total Lymphocyte count was <1200 cells/mm³ in about 48% of 
patients and it shows very good correlation with CD4 count  and p Value 
was statistically significant. 
The patients with TLC <1200 cells/ mm3 had average CD4 count of 121.9 
cells/ µL. Whereas patients with TLC of 1200 to 1800 and  > 1800 cells/mm3 
had  average CD4 count of 266.3 and 565.8 cells/ µL respectively. 
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As shown in Figure 5 ,Of patients with CD4 count <200 cells/µL all of them 
100% (n=45)  are  having TLC <1200 cells/mm³.patients  with CD4 count 
between 200 and 350 were having TLC <1200 cells/mm³ in 9% (n=3)of 
cases and 71% were having TLC >1800/ mm3.Most of the patients with CD4 
count >350 cells/ µL were having TLC >1200 cells/mm³, none were having 
TLC <1200 cells/mm³. 
Figure 6:    BMI AND CD4 COUNT
Figure 7:   HAEMOGLOBIN AND CD4 COUNT
TABLE 13: Body Mass Index and CD4 count
BMI CASES CD4
No. % MEAN SD
<18.5 63 63 203.3 167.1
18.5-24.99 26 26 383.5 249.6
25-29.99 11 11 325.5 181.7
>30 - - - -
Total 100 100 p value 0.0001
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significant
           As shown in the above table and Fig 6, Body mass index  was < 18.5 
kg/m² in 63% and had good correlation with CD4 Count and p value was 
significant. Average CD4 count with BMI <18.5kg/m² was 203.3 cells/ µL.
TABLE 14: Haemoglobin and CD4 count
HB CASES CD4
M F T % MEAN SD
<5 4 6 10 10 136 91
5-8 25 16 41 41 209.7 174.9
8-11 20 11 31 31 282.5 203.4
>11 15 3 18 18 461.8 254.6
Total 64 36 100 100 p value 0.0001
significant
           In our study Haemoglobin  was < 11g% in about 92% (n=33)of 
females and 77% of males (n=49).when correlated  with CD4 count 
showed a statistically significant  p value. patients with HB < 5 g% 
were having mean CD4 count of 136 cells/ µL as shown in Figure 7.
Figure 8:      PLATELETS  AND CD4 COUNT
Figure 9 :      ESR AND CD4 COUNT
TABLE 15: 
PLATELET COUNT AND CD4 COUNT
PLATELET
COUNT
CASES CD4
No. % mean SD
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<150000 54 54 175.1 109.6
>150000 46 46 383.4 256.7
Total 100 100 p value 0.0001
Significant
            As shown in above table platelet count was less than 150000 
in about 54% of cases and it also showed a good correlation with 
CD4 statistically significant p value. The mean CD4 count with PLT 
<150000 cells was only175.1cells/ µL when compared to CD4 count 
of 383.4 cells/ µL with PLT>150000 cells/ mm3 as shown in Figure 8.
TABLE 16: ESR AND CD4 COUNT
ESR CASES CD4
No. % MEAN SD
0-30 35 35 425.7 271
31-60 38 38 206.5 112.3
61-90 21 21 158.9 107.2
>90 6 6 125.2 98.2
Total 100 100 p value 0.0001
significant
   In the above  table, ESR  was > 30mm/hr in about 65% of the cases 
and shows a significant p value with CD4 count. The average CD4 
count with ESR > 90mm/hr was only 125.2 cells/ µL. Patients with 
ESR <30mm/hr were having mean CD4 count of 425.7 cells/ µL as 
shown in Figure 9.
Figure 10:     SERUM ALBUMIN AND CD4 COUNT
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TABLE 17: SERUM ALBUMIN AND CD4 COUNT
SERUM ALBUMIN cases CD4
No. % MEAN SD
<2.8 30 30 150.2 124.9
2.8-3.5 39 39 242 182.2
>3.5 31 31 414.4 244.6
Total 100 100 p value 0.0001
significant
            As shown in above table, serum albumin was less than 3.5g/dl 
in 69% of cases and in 30% of cases it was less than 2.8 g/dl. It has 
good correlation with CD4 and p value was significant.
          As shown in Figure 10 ,patients with serum albumin <2.8 g/dl 
and between 2.8-3.5 g/dl were having mean CD4  count of 150.2 
cells/ µL and 242 cells/ µL respectively. The mean CD4 count of 
patients with s.albumin >3.5 g/dl was 414.4 cells/ µL.
TABLE 18:EFFICACY OF VARIOUS INVESTIGATIONS
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IN VESTIGATIONS
CD4 COUNT
<200 cells/µL >200 cells/µL
No. % No. %
Staging
 III, IV
I,II
42
3
56.8
11.5
32
23
43.2
88.5
TLC Count
<1200 cells /mm³
>1200 cells /mm³
45
-
73.8
-
3
52
6.5
100
Staging + TLC count
Positive
Negative
42
3
93.3
5.5
3
52
6.7
94.5
BMI 
<18.50 kg / m²
>18.50 kg / m²
36
9
57.1
24.3
27
28
42.9
75.7
HB
<11 g/dl
>11g/dl
41
4
50
22.2
41
14
50
77.8
Platelet
<150000 cells/mm³
>150000 cells/mm³
32
13
58.2
28.9
23
32
41.8
71.1
Serum Albumin
<3.5 g/dl
>3.5 g/dl
38
7
55.1
22.6
31
24
44.9
77.4
ESR
>30 mm/hr
<30 mm/hr
35
10
53.8
28.6
30
25
46.2
71.4
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Figure 11:    EFFICACY OF VARIOUS INVESTIGATIONS
TABLE 19: SENSITIVITY ,SPECIFICITY ,PREDICTIVE VALUE OF 
VARIOUS INVESTIGATIONS
INVESTIGATIONS
Efficacy.
True
+ ve
False
+ ve
True
- ve
False
- ve
Sensi
-tivity
Speci-
-ficity
Accu-
-racy
PPV NPV
Staging 42 32 23 3 93 42 65 57 92
TLC Count 45 3 52 - 100 95 97 94 100
Staging + TLC count 42 3 52 3 93 95 94 93 95
BMI 36 27 28 9 80 51 64 57 76
HB g% 41 41 14 4 91 25 55 50 78
TLC+ HBg% 41 3 52 4 91 95 93 93 93
Staging+ HBg% 39 29 26 6 87 47 65 57 81
Platelet 32 23 32 13 71 58 64 58 71
Serum Albumin 38 31 24 7 84 44 62 55 78
ESR 35 30 25 10 78 45 60 54 71
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            As shown in the Table-19, WHO clinical staging  had sensitivity 
93%,specificity 42% in predicting  CD4 count < 200 cells/µL  and it had 
good negative predictive of 92%.Its accuracy was 65%.
          Total Lymphocyte Count   had   sensitivity   100% , specificity 
95%,positive  predictive  value   94%,negative  predictive  value  100%  and 
accuracy  97%.  When  compared  with  WHO staging  TLC had  very  good 
sensitivity,  specificity,  positive  and  negative  predictive  value.TLC  was 
more   accurate than  WHO staging  in predicting CD4 count < 200 cells/µL.
          On combining both WHO staging and TLC, we got sensitivity 93%, 
specificity95%,PPV 93%,NPV 95% and accuracy was 94%.
          BMI had sensitivity and specificity of 80% and 51% respectively. 
Haemoglobin had sensitivity and specificity of 91% and 25% respectively.
           Platelet count had sensitivity 71%   and specificity 58%.serum 
albumin had sensitivity 84% and specificity 44%. ESR had sensitivity and 
specificity of   78% and 45% respectively.
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                              DISCUSSION
                    If CD4 lymphocyte counts are available  and  HIV infected 
patient’s  CD4  lymphocyte  count  is  less  than200  cells/mm3,  it  would  be 
universally agreed that ART should be initiated regardless of the fact that 
CD4 counts have biologic variability by sex, age, and ethnicity as well as 
some variability in measurement in the laboratory.
                   Although the CD4 count has become the ‘‘gold standard,’’ in 
resource-limited  settings  where the  CD4 count  is  not  routinely  available, 
other  clinical  and laboratory  factors  can  be  predictive  of  severe  immune 
compromise.  Routine  hematologic  testing  is  inexpensive  and  widely 
accessible and can provide measurements of the TLC and haemoglobin level. 
                   In our study about 100 patients   are   randomly   enrolled, of 
which  66% are  males  and 34% are  females.  Most  of  the  patients  are  in 
reproductive age group.71% of the patients are in age group between 21 -40 
years. This shows that HIV is more in reproductive age group .This indicates 
a trend of young and productive generation being affected ;a reflection of the 
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devastating effects India will face as the younger generation work force is 
affected. 
In this study age ,number of extra marital  partners,  type of exposure and 
economic status of the patients are very well correlated with CD4 count with 
a statistically significant P value.
                    In our study 54% of patients are having more than one extra 
marital partners and the most common mode of transmission is heterosexual 
route (94%).  This  is  in  consistent  with  Uzgare R et  al50 found  that  the 
percentage  of  various  modes  of  transmission  as  sexual  route 
(93.02%)commonly heterosexual,  Blood (2.32%) , Perinatal(2.32%),surgery 
and IV needles(3.72%).
                  In our study Sex of the patient, Marital status, Premarital sex,  
Education and Occupation are not correlated with CD4 count .
STAGING:
                    WHO in  2005 Proposed a revised clinical staging to initiate 
ART in resource limited settings especially in Africa and Asia.28
                   Clinical events are categorized as those where a presumptive 
clinical diagnosis may be made (conditions that can be diagnosed clinically 
or with basic laboratory tests) and those where a definitive diagnosis may be 
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made (for conditions requiring more complex and sophisticated laboratory 
investigations).
CLINICAL AND IMMUNOLOGICAL CRITERIA FOR INITIATING 
ART IN ADULTS AND ADOLESCENTS
Clinical stage ART
IV Treat.
III Consider  treatment:  CD4,  if  available, 
can guide the urgency with which ART 
should be started.
I ,II Only if CD4 <200/mm3.
Many  studies  were  conducted  to  assess  the  WHO  recommendation  for 
clinical criteria to initiate ART in resource limited settings.
                   In our study using WHO clinical staging III and IV when 
correlated with CD4 count <200 cells/µL we get a significant statistical P 
value 0.0001. It has sensitivity 93%, specificity 42% in predicting   CD4 
count < 200 cells/µL  and it has good NPV of 92%.Its accuracy is 65% and 
PPV is 57%.
Caroline Costello, MPH, Kenrad E. Nelson, MD,Denise J. Jamieson, MD, 
Lisa Spacek, MD, PhD, Supaluk Sennun, MS did a study on “Predictors of 
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LowCD4Count in Resource-Limited Settings”   . This study was based on an 
Antiretroviral-Naive Heterosexual Thai Population. Totally 519 people were 
included in the study. In this study WHO clinical staging III has specificity 
of  90.2%  and  91.7%  and  sensitivity  of  27.4%  and  20.4%   in  men  and 
women. respectively. WHO clinical staging IV has specificity of 100% and 
100% and sensitivity of  2.2% and 1.2%  in men and women respectively
              When compared with above study , our study is having good 
sensitivity of 93%, though it is not specific but the negative predictive value 
is  92% is  good.  Majority  of  the  patients  (74%)  in  our  study  belongs  to 
clinical staging III and IV .So we are getting low specificity when compared 
with above study.
             Patients are categorised in to stage III or IV when they acquire the 
opportunistic infections and other AIDS defining illness as listed in WHO 
staging. Opportunistic infections are more common when CD4 count is less 
than 200 cells/µL.In our study,patients with Stage IV has average CD4 count 
of 136.4 cells/µL and of patients with CD4 count < 200 cells/µL(n=45), 93%
(n=42) were in stage III or IV.
            So clinical staging III and IV is a good predictor of CD4count <200 
cells/ µL.
TOTAL LYMPHOCYTE COUNT:
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              In December 2003, the WHO broadened the recommendations for 
initiation of ART when CD4 testing is unavailable to include WHO stage III 
or IV or WHO stage II in combination with a TLC 1200 cells/mm36,7. Many 
studies have evaluated the use of TLC as a surrogate marker for CD4+ cell 
count with mixed results8,9.  In our study, as shown in TABLE 21,We get a 
sensitivity of  100% specificity of 95% ,accuracy is 95% ,PPV is 94% and 
NPV is 100% for TLC in predicting CD4 count <200 cells/ µL.
               Caroline Costello, MPH, Kenrad E. Nelson, MD43, conducted a 
study on “Predictors ofLowCD4Count in Resource-Limited Settings”. In this 
study TLC <1200 cells/mm3 has specificity of  99.2% in men and 99.5% in 
women. It has sensitivity of 23.4% in men and 13% in women in predicting 
the CD count <200 cells/µL. The TLC was highly correlated with the CD4 
count in this Thai cohort, consistent with studies of HIV-infected patients in 
South , the United kingdom 39, and the United States31.40,41.Similar to above 
study, in our study TLC has very good specificity of 95%.
               Ray Y. Chen, MD, Andrew O. Westfall,  MS,J. Michael 
Hardin44 : Complete Blood Cell Count as a Surrogate CD4 Cell Marker for 
HIV Monitoring in Resource-Limited Settings; This study was conducted in 
The University of Alabama at Birmingham (UAB) Outpatient HIV Clinic. 
According to this study TLC < 1200 cells/mm3has specificity of 90% and 
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sensitivity of 71% in predicting CD4 count< 200 cells/µL. It has PPV OF 
78% and NPV of 87%.
              In comparing with above study, Our study is having very good 
sensitivity(100%),specificity(95%), PPV (94%) and NPV (100%).
              In our study compared to other parameters TLC < 1200 cells/mm3 is 
very  specific  in  predicting  CD4 count  <  200  cells/mm3.  This  is  because 
marked reduction in the CD4+ T cells is the immunologic hallmark if AIDS. 
Productive infection of  T cell and viral replication in infected cells is the 
major mechanism of  lysis of CD4 T cells. The other mechanism of lysis of 
CD4 T lymphocytes are Elimination of HIV-infected cells by virus-specific 
immune  responses,  Activation-induced  cell  death,  Aberrant  intracellular 
signaling events, Apoptosis and Syncytia formation.
                  This decrease in CD4 T cells is directly reflected in total 
lymphocyte count. So, Total Lymphocyte Count  is exact measure of  CD4 T 
cell count .Measurement of peripheral blood CD4 T lymphocytes is probably 
the  most  important  laboratory  assay  for  evaluation  and  monitoring  of 
patients with HIV.The most common technique for measuring CD4 counts in 
developed  country  settings  is  Flow cytometry  which  use  lasers  to  excite 
fluorescent antibody probes specific for various cell surface markers, such as 
CD3,  CD4,  and  CD8,  which  distinguish  one  type  of  lymphocyte  from 
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another. But it is no not widely available in developing countries especially 
in peripheral set up where the HIV prevalence is high. 
           In our study, the patients with TLC <1200 cells/ mm3 has average 
CD4 count of 121.9 cells/ µL .So instead of CD4 count, TLC<1200 cells/mm 
3 which  is more specific marker of CD4 count can be used as a surrogate for 
CD4 count < 200 cell/µL in resource limited settings.
STAGING + TLC :
             On combining both the staging and TLC we are getting a sensitivity 
93%, specificity 95% , accuracy 94%, PPV 93%and NPV 95% in predicting 
CD4 count < 200 cells/µL.
               Schechter M, Leite DM, Zajdenverg R 42  has conducted  a study 
on predictors  of  CD4 count  in  HIV infected Brazilian  individuals  based 
upon WHO clinical staging .171 patients were included in the study. WHO 
clinical  staging  and  absolute  lymphocyte  count  (TLC)  was  significantly 
correlated with CD4 count and has specificity of 89% and PPV OF 85.3%.
              But in our study on using  staging alone has specificity of 42% and 
PPV 57% in predicting CD4 count <200 cells/µL. When using both staging 
and  TLC  the  specificity  increased  from 42  to  95% and  PPV increased 
from57% to 93%.
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              Thus when combining both staging and TLC, the specificity, 
accuracy, PPV and NPV are all increased rather than using staging alone.
BODY MASS INDEX;
            In our BMI has sensitivity 80%, specificity 54% ,accuracy 64%, PPV 
57%and NPV 76% in predicting CD4 count < 200 cells/µL.
           Caroline Costello,  MPH, Kenrad E. Nelson, MD, Predictors 
ofLowCD4Count in Resource-Limited Settings .In this study BMI< 18.5 kg/
m² has specificity of 95.6% and sensitivity of 13.4% in predicting CD4 count 
< 200 cells/µL.
            In our study BMI is more sensitive but less specific when comparing 
with above study in predicting CD4 count < 200 cells/µL. This is because 
low BMI is more prevalent(63%) in our study which decrease the specificity. 
The BMI is  low in our  study because most  of  our  patients  are  in  WHO 
staging  III  and  IV  ,they  are  having  more  opportunistic  infections  and 
succumb  to  cachectic  process  and  muscle  wasting  due  to  inflammatory 
cytokines30.
 BMI <18.5kg/m2  is more common in stage III and IV when CD4 count is 
<200 cells/ µL .Thus it is useful in predicting CD4 count <200 cells/µL.
ANAEMIA; 
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           Anaemia is more common in our country. In our study about 
82% of the patient   are anaemic.92% (n=33)of females and 77% of 
males (n=49) were anaemic in our study. patients with HB < 5 g% 
were having mean CD4 count of 136 cells/ µL. Anaemia very well 
correlated with CD4 count with a statistically significant P value of 
0.0001.
          Anaemia has sensitivity 91%, specificity 25% , accuracy 55%, PPV 
50%and NPV 78% in predicting CD4 count < 200 cells/µL.
                  47Belperio PS, Rhew DC. Prevalence   and outcomes of anaemia  in 
individuals  with  human  immunodeficiency  virus.  In  this  study  it  was 
anaemia  more  commonly  associated  with  disease  progression  with 
progressive  decrease  in  CD4  count  and  anaemia  was  more  common  in 
females when compared to females. Caroline Costello, MPH, Kenrad E. 
Nelson, MD, Predictors of  Low CD4Count in Resource-Limited Settings. In 
this  study  also  anaemia  more  common  in  females  (15.6%)  compared  to 
males(9%) and the specificity  of  anaemia  in  predicting CD4 count  <200 
cells/µL was 96.4% and 85.5% in males and females respectively. Among 
men  in  this  study  ,  anaemia  was  highly  predictive  of  CD4  count  <200 
cells/µL .
             Compared to above study, our present study has good sensitivity of 
91% and specificity is only 25% . This is mainly due to,  as  anaemia is more 
prevalent  in  our  country  the  specificity  in  predicting  CD4  count  <  200 
cells/µL is very low.
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              Anaemia in the setting of HIV is due to multifactorial causes and it  
is the most common hematologic abnormality in HIV-infected patients. As 
most  of  our  patients  are  in  WHO staging III  and IV the most  important 
causes  are  systemic  fungal  and  mycobacterial  infections,  nutritional 
deficiencies, and vitamin B12 levels may be depressed as a consequence of 
achlorhydria  or malabsorption.
            Anaemia  when combined with TLC count,  we are  getting a 
sensitivity 91%, specificity 95% ,accuracy 93%, PPV 93%and NPV 93% in 
predicting CD4 count < 200 cells/µL.
          When combining anaemia with TLC specificity, accuracy of the test, 
PPV and NPV are all increased  rather than using anaemia alone.
           Thus anaemia combined with TLC count can be used as a more 
sensitive and specific test in predicting CD4 count <200 cells/µL in resource 
limited settings in primary health care centres in our country.
PLATELET COUNT:
             The prevalence of thrombocytopenia in our study is 55% of which 
58% of patients are having  CD4 count <200 cells/µL. The platelet count 
decreases progressively with decrease in CD4 count and more common in 
AIDS.
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            In present study platelet count  has sensitivity 71%, specificity 
58% ,accuracy 64%, PPV 58% and NPV 71% in predicting CD4 count < 200 
cells/µL. It shows a significant correlation with CD4 count with a significant 
P value of 0.0001.
           In HIV positive patients ,according to Sullivan PS,Hanson DL et al45 
isolated  thrombocytopenia  may  be  early  consequences  of  HIV  infection. 
Fauci et al Harrison's principles of internal medicine27 AIDS and related 
disorders  mentioned   approximately  3%  of  patients  with  untreated  HIV 
infection  and  CD4+  T  cell  counts  ³400/µL  have  platelet  counts 
<150,000/µL. For untreated patients with CD4+ T cell counts <400/µL, this 
incidence increases to 10%.In our study the prevalence of thrombocytopenia 
is 58% with CD4 count <200 cells/µL.
 The low platelet count in our study  is explained by
1.Anti  gp  120  and  gp  41antibody  are  removed  from  circulation  by 
macrophages in the Spleen, similar to mechanism seen in ITP.
2.  due to a direct effect of HIV on megakaryocytes.
In our study, in patients with PLT <150000 cells the mean CD4 count was 
only  175.1cells/ µL .Though  the  platelet  count  has  low  specificity  and 
sensitivity when compared to TLC ,as it is more prevalent when CD4 count 
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< 200 cells/µL, it may be used in addition to TLC in predicting CD4 count < 
200 cells/µL.
ERYTHROCYTE SEDIMENTATION RATE:
             ESR  is  a marker of ongoing inflammation. In the setting of 
HIV, ESR is very much increased in various opportunistic infections 
especially tuberculosis when CD4 count is <200 cells/µL. ESR in our 
study is more than 30mm/hr in about 65% of the cases and shows a 
significant P value with CD4 count. Of the whole 65% of cases with 
ESR >30mm/hr about 70% of the  patients are having CD4 count < 
200 cells/µL.
            Most of the patients (74%)in our study come under WHO clinical 
staging  III  and IV  who are  having opportunistic   infections.  so  ESR is 
naturally raised with progressive decrease in CD4 count and  the average 
CD4 count with ESR > 90mm/hr was only 125.2 cells/ µL. Thus ESR may 
be used as an additional test along with TLC, in predicting CD4 count < 200 
cells/µL.
SERUM ALBUMIN:
            In present study Sr.Albumin levels decreases progressively 
with progression of disease to AIDS. It correlate well with low CD4 
count. About 69% of  the patients are having serum albumin <3.5 g% 
and most of them (55%) are having CD4 count < 200 cells/µL.
           Serum albumin  has sensitivity 84%, specificity 44% ,accuracy 62%, 
PPV 55% and NPV 78% in predicting CD4 count < 200 cells/µL in our 
study.
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            Joseph G. Feldman46, Stephen J. Gange , conducted a 
study on “Serum Albumin Is a Powerful Predictor of Survival among 
HIV-1–Infected Women”. According to this study Albumin fell 
progressively with decrease in CD4 count at a rate of 0.44 g/L/y in 
1627 women who survived and at a faster rate in 397 who died (1.54 
g/L/y; p < .01). In a time-dependent model adjusting for disease 
markers, the relative hazard (RH) was fivefold higher in patients with 
serum albumin <35 g/L compared with patients with serum albumin 
>42g/L. Even though serum albumin is not a specific marker  for 
HIV-1 infection, it was one of the strongest independent predictors of 
mortality46.
In our study , patients with serum albumin <2.8 g/dl  are having mean CD4 
count of 150.2 cells/ µL .Progressive decrease in Sr. Albumin with decline in 
CD4 count is explained in our study by the following:
1.Because HIV infection is known to be associated with systemic 
inflammation and elevations in the levels of pro inflammatory 
cytokines, which can suppress albumin35 synthesis.
2. The HIV-1 Tat-1 protein may disrupt the barrier function of the 
endothelium, resulting in both an increase in trans capillary escape of 
albumin and the dissemination of HIV-infected cells into tissue and, 
consequently, disease progression36.
3. HIV-related anorexia may depress albumin synthesis.
Thus  serum  albumin  is  a  very  good  marker  associated  with  disease 
progression. It may be used as a predictor of CD4 count < 200 cells/µL in 
addition to TLC.
                                 CONCLUSION
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1.TLC<1200  cells/mm3  is  the   most  sensitive  and  specific  test  and  best 
predictor of CD4 count < 200 cells/µL, whereas WHO staging is a good 
sensitive test.
2. TLC along with WHO staging or Anaemia, is more specific in predicting 
CD4 count <200 cells/µL , rather than using staging or anaemia  alone.
 3. Though BMI, Anaemia ,platelet count, ESR and serum albumin  are good 
predictors of CD4 count < 200 cells/µL, these  tests are less sensitive and 
specific when compared to TLC or staging.
4.  Platelet  count  and  Serum  Albumin  level  decreases  with  progressive 
decrease in  CD4 count.  Platelet  count  <150000/mm³ and s.albumin <2.8 
g/dl are also good predictors of CD4 count <200/µL.
Although  the  CD4  count  is  used  as  “gold  standard”  test,  TLC  <  1200 
cells/mm³ or  TLC along with WHO staging or anaemia can be used as a 
surrogate marker for CD4 count <200 cells/µL to initiate ART in resource 
limited settings.
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                                             SUMMARY
            This study  “PREDICTORS OF CD4 COUNT IN HIV INFECTED 
PATIENTS” , was conducted in 100 HIV positive patients who were attended 
the ART medical centre in Govt. Rajaji Hospital ,Madurai from June 08 to 
June 2009.
            In our study 100 patients were randomly selected of  which 66% 
were males and 34% were females. About 74% were in age group between 
21- 40 years showed the prevalence of disease in reproductive age group.
             In all the patients  various clinical and inexpensive laboratory 
measures such as WHO clinical Staging ,BMI ,Total  Lymphocyte  Count 
(TLC),haemoglobin  ,platelet  count,   ESR,  S.  Albumin   were  done  and 
correlated  with CD4 count .It was  analysed that these parameters may be 
used as a surrogate marker for CD4 count to initiate ART and to monitor 
therapy.
        WHO staging III and IV  had sensitivity of 93% and specificity of 25% 
in  predicting  CD4  count  <  200  cells/µL  and  it  showed  a  significant 
correlation with CD4 count.
         TLC <1200 cells/mm3 had sensitivity of 100% and specificity of 95% 
in  predicting  CD4  count  <200  cells/µL  and  it  showed   a  statistically 
significant correlation with CD4 count.
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                BMI<18.5kg/m2,Haemoglobin<11g%,Platelets<150000cells/mm3,
ESR  >30mm/hr  and  s.albumin<3.5g/dl  showed  a  statistically  significant 
correlation with CD4 count but  they were less sensitive and less specific 
when compared to TLC or WHO staging.
             Therefore TLC is most sensitive and specific best predictor of CD4 
count <200 cells/µL.
            WHO clinical  staging is a good sensitive test in predicting CD4 
count  less than 200 cells/µL.
              TLC when combined with WHO staging or Anaemia, specificity in 
predicting CD4 count <200 cells/µL increases, than using staging or anaemia 
alone.
            Although the CD4 count has become the  “gold standard”, TLC < 
1200 cells/mm³ or  TLC along with WHO staging or anaemia may be used 
as  a  surrogate  marker  for  CD4  count  <200  cells/µL  to  initiate  ART  in 
resource limited settings.
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                                     PROFORMA
Name                                                         
Age                   
Sex 
ART No.                   
Address 
Occupation                                           
Education -   < 10 th /10-12 th/higher education                             
Economic status-upper/middle/lower
Marital status- single /married /separated
Premarital sex-yes/no
Extra Marital Patners
Exposure- heterosexual/homosexual/IV drug abuser/blood transfusion
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CLINICAL  WHO  STAGING  HISTORY  AND EXAMINATION 
•  Persistent generalized lymphadenopathy
• Moderate and unexplained weight loss 
• Recurrent  respiratory  tract  infections  (such  as  sinusitis,  bronchitis, 
otitis media, pharyngitis)
• Herpes zoster
• Recurrent oral ulcerations
• Papular pruritic eruptions
• Angular cheilitis
• Seborrhoeic dermatitis
• Fungal finger nail infections 
• Unexplained persistent fever 
• Unexplained chronic diarrhoea for longer than one month
• Oral candidiasis
• Oral hairy leukoplakia
• Pulmonary tuberculosis (TB) diagnosed in last two years
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• Severe  presumed  bacterial  infections  (e.g.  pneumonia,  empyema, 
meningitis, bacteraemia, pyomyositis, bone or joint infection)
• Acute necrotizing ulcerative stomatitis, gingivitis or periodontitis
• HIV wasting syndrome
• Pneumocystis pneumonia
• Recurrent severe or radiological bacterial pneumonia
• Oesophageal candidiasis
• Extrapulmonary Tuberculosis
WHO STAGING   :    I ,II, III, IV
PAST HISTORY        DM  ,  HT ,   BA ,   PT ( CAT   I   II  III), STD, 
HEPB
FAMILY HISTORY                                      
GYNAECOLOGICAL   HISTORY  for females     
PERSONAL HISTORY- Smoking      Alcohol       Tobacco      Drug Abuse 
ANTHROPOMETRY       
 HT          cm     
WT        Kg        
BMI         kg/m2    
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INVESTIGATIONS 
Hb                                                                          HIV ELISA
Tc                                                                          CD4 Count
Dc                                                                          Chest Xray 
Platelet Count                                                        Sptum For AFB
ESR                                                                       VDRL
Serum Albumin                                                     OGD Scopy
Blood Sugar
Blood Urea
Serum Creatinine
Lipid Profile
Total Bilirubin
            Direct/Indirect
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